Skip to main content
NCBI home page
Frontiers in Oncology logoLink to Frontiers in Oncology
. 2022 Mar 17;12:846568. doi: 10.3389/fonc.2022.846568

The Value of Shear Wave Elastography in the Diagnosis of Breast Cancer Axillary Lymph Node Metastasis and Its Correlation With Molecular Classification of Breast Masses

Changyun Luo 1,†, Li Lu 2,†, Weifu Zhang 3, Xiangqi Li 4, Ping Zhou 5, Zhangshen Ran 1,*
PMCID: PMC8968036  PMID: 35372023

Abstract

Objective

To explore the diagnostic value of shear wave elastography examination (SWE) on axillary node metastasis (ANM) in breast cancer, this study aimed to evaluate the correlation between the SWE features and different molecular types of breast cancer, and to check the elastic modulus differences among the molecular types.

Methods

Breast cancer patients from November 2020 to December 2021 were subjected to both conventional ultrasonic examination (CUE) and SWE before ultrasound-guided percutaneous biopsy or axillary lymph node dissection (ALND). We used the pathological results as the gold standard to draw the receiver operating characteristic (ROC) curve.

Results

SWE outperforms CUE, but their conjunctive use is the best option. No significant correlation was found between the elastic modulus values and the molecular types of breast cancer.

Conclusion

SWE can be used as an routine auxiliary method of CUE for ANM.

Keywords: shear wave elastography, breast cancer, metastasis, molecular classification, diagnosis

Introduction

In the 21st century, cancer is the top cause of death in hospitals and the key limitation of life expectancy in most countries, whatever level their economics and social civilization (1, 2). The Global Cancer Statistics Report published by the United States Cancer Research Institute shows that breast cancer surpassed lung cancer in 2020, becoming the most common type of cancer among female patients and the main cause of death for female patients in 185 countries (3). According to statistics, 19.3 million people were diagnosis with cancer and nearly 10 million deaths worldwide in 2020 were because of cancer (4). Around 2.3 million new-onset cases are of female breast cancer accounting for 11.7%, and breast cancer causes 0.69 million deaths which account for 6.9% of all global cancer deaths (5). In fact, 1 in every 18 women will develop breast cancer globally, and the clinical manifestations and prognosis of patients are different (6). Age, molecular subtype, and axillary lymph node status are considered to be independent factors affecting the prognosis of patients suffering from breast cancer (7). In addition, tumor-related factors such as pathological type, grade, and stage can also explain the higher mortality of breast cancer to a certain extent (8).

With the development of molecular biology, it has been recognized that breast cancer has large biological diversity and high heterogeneity, which result in different morphological subtypes, recurrence rate, targeted therapy strategies, and survival risks (9–11). Therefore, if the patients with breast cancer can be accurately classified, it should help to select individualized precision treatment and effectively predict the prognosis (12–14). According to immunohistochemical indexes such as estrogen receptor (ER), progesterone receptor (PR), proliferating cell nuclear antigen (Ki-67), and human epidermal growth factor receptor-2 (HER-2), clinicians determine the molecular subtype of breast cancer, namely luminal A, luminal B, Her-2-positive, and triple-negative breast cancer (TNBC) (15–18), where HER2-positive includes HR-negative and HR-positive (15, 19–23). The status of axillary lymph nodes is also an important factor influencing the prognosis of patients. According to reports, 70-80% of early non-metastatic breast cancer patients can be cured. Patients with advanced breast cancer and distant organ metastasis are considered to be incurable by existing therapies. The prognosis of patients with advanced breast cancer is poor, and the 5-year survival rate is only 20% (24). In addition, the axillary lymph node (ALN) is deemed as the first site to be metastasized by breast cancer through the lymphatic vessels (25).

Shear wave elastography examination (SWE) is a newly emerging elastography technique, which can display tissue stiffness in a quantified form to obtain the biological information of the primary lesion (26–30). At present, many studies have verified the diagnostic value of SWE for benign and malignant lesions in breasts (31–34). The technique has been widely employed to check the thyroid, pancreas, kidney, prostate, liver, and other organs while few studies about axillary node metastasis (ANM) and its application for the molecular classification of breast cancer were reported (35–39). Here, we applied SWE to assess the axillary node status of patients with breast cancer with a goal to explore its feasibility in the diagnosis of ANM, and to check the relationship of the SWE elastic modulus and the molecular types of breast cancer.

Materials and Methods

Research Objects

After the pathological verification for breast cancer, 114 patients who had never received any treatment were recruited in the Second Affiliated Hospital of Shandong First Medical University from November 2020 to December 2021 (40). The mean age is 52.52 ± 9.03 (range, 31-75 years old), and the mean long diameter of the lymph node is 1.60 ± 0.70 (range, 0.5 ± 4.8 cm). All of the patients underwent conventional ultrasonic examination (CUE) before ultrasound-guided percutaneous biopsy on the axillary lode or axillary lymph node dissection (ALND). Some key indexes were scored (see Table 1 ) . This program was approved by the Medical Ethics Committee of the Second Affiliated Hospital of Shandong First Medical University.

Table 1.

Criteria and evaluation of CUE in the diagnosis of lymph node status.

Index 1 point 2 point
Aspect ratio >2 <2
Short axis diameter <7 mm >7 mm
Lymphatic hilus Yes No
Cortical thickness <3 mm >3 mm
Blood flow type Gate type Peripheral type or mixed type
Open in a new tab

Shear Wave Elastography Examination

The Toshiba Apio500 ultrasonic diagnostic machine equipped with high-frequency linear array probe PLY-805AT (2.0-12.0 MHZ) called shear wave was used for SWE. Based on the operations of Skerl et al., the parameters of SWE were set when ROI = 2 mm (41). Both of the transverse and the longitudinal sections of each breast mass and suspicious lymph node were measured three times to obtain average values.

Image Analysis

Two physicians who have more than 5 years of experience in breast and axillary lymph node diagnosis analyzed the image results. A score was evaluated based on the aspect ratio and the short axis diameter of the lymph node (42). Plus, the maximum value (Emax), average value (Emean), and minimum value (Emin) of Young’s modulus were assessed by SWE, and a static image was kept (43, 44). Afterwards, univariate analysis was performed using ALN metastasis as a dependent variable and the CUE scores. The obtained indexes with statistical significance were extracted for multivariate logistic regression analysis with the Emean of SWE as independent variables. In the predictive model, ANMs were confirmed as benign or malignant lesions. Then, the predictive results were compared with the below pathological results to draw the gold standard receiver operating characteristic (ROC) curves and get the area under the curve (AUC) values.

The patients who underwent surgical treatment were classified into four groups according to their molecular classification results to check whether the elastic modulus values of SWE ​​were statistically different between the groups, and explore its relationship with the classification strategy.

Pathological Examination

Ultrasound-guided axillary nodal puncture was accomplished in 62 patients and breast mass resection was done in 86 patients. Tissue biopsy including postoperative pathological section and immunohistochemical examination was implemented (45, 46).

Statistical Analysis

SPSS 25.0 software was used to process the above data. The measured data were expressed as mean ± standard deviation, and the count data were expressed as rate (%). The chi-square test was used to compare the two-category data between the two groups, and the KAPPA test was used to compare the consistency of the diagnosis results of CUE, SWE, and their conjunctive usage with the pathological results. Multivariate logistic regression analysis was used to construct a prediction model of CUE combined with SWE to obtain the prediction probability.

Results

Pathological Results

A total of 114 women with breast cancer were enrolled in this study, who were then divided into two groups: the ANM group with 58 cases and the non-metastasis group with 56 cases. The mean age, medical course, and ALN size in the former group were 49.59 ± 8.54 years, 11.0 ± 25.22 months, and 2.16 ± 2.63 cm. In the latter group, the same data were 51.48 ± 9.50 years, 5.70 ± 14.27 months, and 1.36 ± 0.51 cm.

Comparison of the Two Groups With/Without ANM

As Table 2 shows, on one hand, the CUE comparison displayed significant differences in lymph nodal size, aspect ratio, and short axis diameter. However, the hilum structures, cortex thicknesses, and blood-flow types did not show any difference. On the other hand, the SWE comparison also showed significant differences in the Emax, Emean, and Emin values.

Table 2.

Comparison of CUE and SWE elastic modulus between the two groups with/without ANM.

No lymph node metastases Lymph node metastases T/X2 p value
Lymph node size 1.36 ± 0.51 2.16 ± 2.63 -2.218 0.029
Aspect ratio >2 41 (73.2%) 13 (22.4%)
<2 15 (26.8%) 45 (77.6%) 29.49 0
Short axis diameter <7 44 19 24.18 0
>7 12 39
Lymphatic hilus 26 26 0.029 0.864
No lymphatic hilus 30 32
Gate type 28 21 2.21 0.137
Not gate type 28 37
Cortical thickness <3 11 13 0.13 0.717
>3 45 45
Emax 24.68 ± 18.91 77.68 ± 48.06 -7.693 0
Emean 17.34 ± 14.13 58.33 ± 42.31 -6.887 0
Emin 13.35 ± 10.39 39.77 ± 36.79 -5.255 0
Open in a new tab

Comparison of the Consistency Between the Diagnosis Results of the Three Medical Means and the Pathological Outcomes

In the CUE assessment for ANM, as Table 3 shows, compared with the pathological results, the accuracy, sensitivity, specificity, positive predictive value, and negative predictive value calculated from the exclusive usage of CUE in the diagnosis of malignant lymph nodes were 65.8%, 72.4%, 58.9%, 64.6%, and 67.3%, respectively. As a result, the whole consistency with the pathological results was 0.314.

Table 3.

Comparison of diagnostic efficacy of CUE, SWE, and their conjunctive use in ANM.

Sensitivity Specificity Positive predictive value Negative predictive value Accuracy Kappa
CUE 72.40% 58.90% 64.60% 67.30% 65.80% 0.314
SWE 70.70% 76.70% 75.90% 71.60% 73.60% 0.474
CUE+SWE 79.30% 82.10% 82.10% 79.30% 80.70% 0.616
Open in a new tab

In the SWE assessment for ANM, according to the literature, Emean>18.7 was set as the metastatic threshold of the lymph nodes. When the average stiffness of the lymph node was greater than 18.7 Kpa, we believed that the lymph node was more likely to be malignant. On the contrary, the lymph node was more likely to be benign. Compared with the pathological results, the sensitivity, specificity, and positive and negative predictive value of SWE for malignancy were 70.7%, 76.7%, 75.9%, and 71.6%, respectively, which resulted in a diagnostic accuracy of 73.6%, and the consistency with the pathological result was 0.474.

In the conjunctive use of CUE and SWE to assess ANM, whether metastasis exists was used as the dependent variable and the indicators observed by CUE were used as independent variables, and univariate analysis was performed. It was found that the aspect ratio and short axis diameter of lymph nodes observed by CUE were statistically significant with ANM. Then, taking the average elastic modulus of SWE, the aspect ratio of the lymph node, and the short axis diameter of the lymph node as the independent variables into the multivariate logistic regression, a predictive model was constructed. The results show that Emean and both the aspect ratio of the lymph node and the short axis diameter of the lymph node can be entered into the equation.

Based on the above results, three ROC curves were drawn and the corresponding AUC values were calculated (see Figure 1 ).The results showed that conjunctive use (AUC, 0.88) had the best predictive ability compared to exclusive use of CUE (AUC, 0.657) or SWE (AUC, 0.737).

Figure 1.

Figure 1

Open in a new tab

Three ROC curves for the sensitivity and specificity of CUE, SWE, and their conjunctive use in ANM diagnosis.

The Best Cut-Off Value of SWE for the Diagnosis of ANM

Although many studies have shown that quantitative SWE can help diagnose breast diseases, the cut-off values used were different. In order to evaluate the optimal SWE parameters to quantify ANM, ROC curves for Emax, Emean, and Emin were also drawn. We suggest that when Emean=23.2 is used as the cut-off value, SWE is the best (see Figure 2 ).

Figure 2.

Figure 2

Open in a new tab

Three ROC curves for the sensitivity and specificity of the Emean, Emax, and Emin in the application of ANM diagnosis.

The SWE Elastic Modulus Value and Analysis of Variance Results of Different Molecular Types of Breast Cancer

According to the expression of ER, PR, HER-2, and Ki-67, 86 people who underwent surgery were divided into six groups (19, 47). Variance analysis on the elastic modulus values for each group was performed. We found that all of the comparisons of Emax, Emean, and Emin between the molecular types did not have statistical significance (see Table 4 ).

Table 4.

Variance analysis of SWE elastic modulus and different molecular subtypes of breast cancer.

Emax (Kpa) Emean (Kpa) Emin (Kpa)
Luminal A type 119.04 ± 17.63 88.07 ± 23.02 59.53 ± 24.19
Luminal B type 112.43 ± 14.62 80.97 ± 11.65 51.07 ± 10.29
HER-2 high expression 119.51 ± 21.60 89.19 ± 21.03 60.50 ± 20.82
Triple-negative 126.87 ± 16.45 98.14 ± 17.53 68.90 ± 16.53
F 1.372 1.714 1.719
P 0.257 0.171 0.169
Open in a new tab

Discussion

Worldwide, the incidence and mortality of breast cancer always takes the top cancer spot in female patients (3). Several reports show that the incidence of breast cancer has been increasing year by year in the past 5 years (48, 49), and the choice of treatment strategy is determined by the state of ALNs, which decide the final bill of the patients (50). Therefore, it is substantially important to correctly assess the status of ALNs in breast cancer patients before surgery.

Although CUE has high sensitivity in the diagnosis of breast cancer, some previous studies have found that the accuracy, sensitivity, and specificity of ultrasound in diagnosing ALN metastasis is not so high (51–53). The concept of SWE was first proposed by Sarvazyan et al. in 1998 (54). Its principle is to use acoustic radiation force pulses (ARFI) to apply pressure to the tissues to induce mechanical vibrations in the tissues. In the process, by collecting the shear echo signal reflected by the tissue vibration, the propagation speed in the tissue can by calculated and automatically converted into the elastic modulus value through the conversion system. Consequently, the hardness information of the tissue can be quantified (55). Nowadays, a large number of studies have shown that the advantages of SWE in the application of breast, thyroid, prostate, liver, and other organs, but no research has reported the assessment of ALN metastasis. Besides, there is no standard for the cut-off value of SWE in the diagnosis of metastatic lymph nodes.

In this study, the Emax, Emean, and Emin of the lymph node metastasis group were all higher than those of the lymph node non-metastasis group, and the difference was statistically significant (p<0.05). The average elasticity of benign and malignant lymph nodes was 17.34 Kpa and 58.33 Kpa, respectively. The average value we obtained was higher than some previous studies, which may be longer than the course of some breast cancer patients in our study. The tumor cells synthesize a large number of collagen fibers and lymphocytes in the tumor microenvironment during the process of metastasis. Infiltration changes increased the stiffness of the lymph nodes in this part of the patients, leading to a corresponding increase in the average stiffness of the lymph node metastasis group. In this study, Emean=18.7 kpa was selected as the critical value of metastatic lymph nodes. A preliminary exploration was carried out on shear wave elastography to assess lymph node metastasis. A total of 114 lymph nodes were examined by shear wave elastography, and 41 cases of metastatic lymph nodes were correctly diagnosed, which were benign. There were 43 cases of lymph nodes and 30 cases of misdiagnosis. Its specificity (76.7%) and accuracy (73.6%) were higher than those of conventional ultrasound, but its sensitivity (70.7%) was lower, so it could not be used as a substitute for conventional ultrasound. The reasons for the misdiagnosis included: 1) It may be because the volume of some lymph nodes is relatively small or the location is relatively deep. Affected by the anatomical structure of the axilla, the shear wave cannot spread well, resulting in a low measured elastic modulus value. 2) There may be liquefaction and necrosis in some malignant lymph nodes, and there are relatively few elastic and collagen fibers in them, so the measured elastic modulus value is not high.

Additionally, as we believe that the average stiffness of metastatic lymph nodes has the highest specificity, the conjunctive use of Emean and CUE can form complementary advantages, obtaining more objective information to determine which lymph nodes are suitable for biopsy. However, up to now, the optimal cut-off value of each parameter of SWE has not yet reached agreement. It may be affected by many factors, such as pre-compression, the machine model and the depth of the lesion, and the progression of the patient’s disease (56, 57). Therefore, studies with a larger sample size involving multiple units should be considered. Plus, we tried to employ SWE to predict the molecular type of breast cancer with the elastic modulus values (58, 59). Unfortunately, no significant difference was found ​​between the six different groups. This is in line with the conclusion drawn by previously published papers (60, 61). As a result, we do not recommend the implementation of the molecular classification of breast cancer via SWE at this stage. However, with the increase of clinical experience, doctors have gradually realized the value of SWE in the diagnosis of breast cancer axillary lymph node metastasis (62–65).

Data Availability Statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Ethics Statement

The study was approved by the Medical Ethics Committee of the Second Affiliated Hospital of Shandong First Medical University.

Author Contributions

ZSR designed the study. WZ and XL recruited the patients and summarized their medical records. CL and LL performed the data analysis and wrote the manuscript. PZ revised the manuscript. All the authors made a direct and intellectual contribution to this topic and approved the article for publication.

Funding

This work was supported by grants from the Shandong Province Traditional Chinese Medicine Science and Technology Development Plan (No. 2015-266); the Shandong First Medical University Academic Improvement Plan (No. 2019QL017); the Shandong Province Medicine and Health Science and Technology Development Plan (No. 202009020793); the Shandong Province Natural Science Foundation (No. ZR2020MH357); and the Tai’an Science and Technology Innovation Development Project (No. 2020NS205).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Acknowledgments

We thank all the individuals who have helped us in this study. We acknowledge the valuable work of the many investigators whose published articles we were unable to cite owing to space limitations.

References

  • 1. Global Burden of Disease Cancer, C. Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Group to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol (2019) 5(12):1749–68. doi:  10.1001/jamaoncol.2019.2996 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics 2020. Chin Med J (Engl) (2021) 134(7):783–91. doi:  10.1097/CM9.0000000000001474 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Coughlin SS. Epidemiology of Breast Cancer in Women. Adv Exp Med Biol (2019) 1152:9–29. doi:  10.1007/978-3-030-20301-6_2 [DOI] [PubMed] [Google Scholar]
  • 4. Youlden DR, Cramb SM, Yip CH, Baade PD. Incidence and Mortality of Female Breast Cancer in the Asia-Pacific Region. Cancer Biol Med (2014) 11(2):101–15. doi:  10.7497/j.issn.2095-3941.2014.02.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2021) 71(3):209–49. doi:  10.3322/caac.21660 [DOI] [PubMed] [Google Scholar]
  • 6. Thorat MA, Balasubramanian R. Breast Cancer Prevention in High-Risk Women. Best Pract Res Clin Obstet Gynaecol (2020) 65:18–31. doi:  10.1016/j.bpobgyn.2019.11.006 [DOI] [PubMed] [Google Scholar]
  • 7. Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast Cancer. Lancet (2021) 397(10286):1750–69. doi:  10.1016/s0140-6736(20)32381-3 [DOI] [PubMed] [Google Scholar]
  • 8. Johansson ALV, Trewin CB, Hjerkind KV, Ellingjord-Dale M, Johannesen TB, Ursin G. Breast Cancer-Specific Survival by Clinical Subtype After 7 Years Follow-Up of Young and Elderly Women in a Nationwide Cohort. Int J Cancer (2019) 144(6):1251–61. doi:  10.1002/ijc.31950 [DOI] [PubMed] [Google Scholar]
  • 9. Jin L, Han B, Siegel E, Cui Y, Giuliano A, Cui X. Breast Cancer Lung Metastasis: Molecular Biology and Therapeutic Implications. Cancer Biol Ther (2018) 19(10):858–68. doi:  10.1080/15384047.2018.1456599 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA (2019) 321(3):288–300. doi:  10.1001/jama.2018.19323 [DOI] [PubMed] [Google Scholar]
  • 11. Khrouf S, Ksontini FL, Ayadi M, Rais HBA, Mezlini A. Breast Cancer Screening- a Dividing Controversy. Tunis Med (2020) 98(1):22–34. [PubMed] [Google Scholar]
  • 12. Tsang JYS, Tse GM. Molecular Classification of Breast Cancer. Adv Anat Pathol (1998) 27(1):27–35. doi: 10.1097/PAP.0000000000000232 [DOI] [PubMed] [Google Scholar]
  • 13. Cejalvo JM, Martinez de Duenas E, Galvan P, Garcia-Recio S, Burgues Gasion O, Pare L, et al. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. Cancer Res (2017) 77(9):2213–21. doi:  10.1158/0008-5472.CAN-16-2717 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, et al. De-Escalating and Escalating Treatments for Early-Stage Breast Cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol (2017) 28(8):1700–12. doi:  10.1093/annonc/mdx308 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular Alterations in Triple-Negative Breast Cancer—the Road to New Treatment Strategies. Lancet (2017) 389(10087):2430–42. doi:  10.1016/s0140-6736(16)32454-0 [DOI] [PubMed] [Google Scholar]
  • 16. Garrido-Castro AC, Lin NU, Polyak K. Insights Into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discov (2019) 9(2):176–98. doi:  10.1158/2159-8290.CD-18-1177 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Chang-Qing Y, Jie L, Shi-Qi Z, Kun Z, Zi-Qian G, Ran X, et al. Recent Treatment Progress of Triple Negative Breast Cancer. Prog Biophys Mol Biol (2020) 151:40–53. doi:  10.1016/j.pbiomolbio.2019.11.007 [DOI] [PubMed] [Google Scholar]
  • 18. Won KA, Spruck C. Triplenegative Breast Cancer Therapy: Current and Future Perspectives (Review). Int J Oncol (2020) 57(6):1245–61. doi:  10.3892/ijo.2020.5135 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Rakha EA, Green AR. Molecular Classification of Breast Cancer: What the Pathologist Needs to Know. Pathology (2017) 49(2):111–9. doi:  10.1016/j.pathol.2016.10.012 [DOI] [PubMed] [Google Scholar]
  • 20. Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer- American Society of Clinical Oncology:College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol (2018) 36(20):2105–22. doi:  10.1200/JCO.2018 [DOI] [PubMed] [Google Scholar]
  • 21. Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, et al. Breast Cancer: Biology, Biomarkers, and Treatments. Int Immunopharmacol (2020) 84:106535. doi:  10.1016/j.intimp.2020.106535 [DOI] [PubMed] [Google Scholar]
  • 22. Kreutzfeldt J, Rozeboom B, Dey N, De P. The Trastuzumab Era- Current and Upcoming Targeted HER2+ Breast Cancer Therapies. Am J Cancer Res (2020) 10(4):1045–67. [PMC free article] [PubMed] [Google Scholar]
  • 23. Ruschoff J, Nagelmeier I, Jasani B, Stoss O. ISH-Based HER2 Diagnostics. Pathologe (2021) 42(Suppl 1):62–8. doi:  10.1007/s00292-020-00878-6 [DOI] [PubMed] [Google Scholar]
  • 24. Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast Cancer. Nat Rev Dis Primers (2019) 5(1):66. doi:  10.1038/s41572-019-0111-2 [DOI] [PubMed] [Google Scholar]
  • 25. Chas M, Boivin L, Arbion F, Jourdan ML, Body G, Ouldamer L. Clinicopathologic Predictors of Lymph Node Metastasis in Breast Cancer Patients According to Molecular Subtype. J Gynecol Obstet Hum Reprod (2018) 47(1):9–15. doi:  10.1016/j.jogoh.2017.10.008 [DOI] [PubMed] [Google Scholar]
  • 26. Sarvazyan AP, Skovoroda AR, Emelianov SY, Fowlkes JB, Pipe JG, Adler RS, et al. Biophysical Bases of Elasticity Imaging. Acoustical Imaging (1995) 21:223–40. doi: 10.1007/978-1-4615-1943-0_23 [DOI] [Google Scholar]
  • 27. Bercoff J, Tanter M, Fink M. Supersonic Shear Imaging- A New Technique for Soft Tissue Elasticity Mapping. IEEE Trans Ultrason Ferroelectr Freq Control (2004) 51(4):396–409. doi: 10.1109/TUFFC.2004.1295425 [DOI] [PubMed] [Google Scholar]
  • 28. Athanasiou A, Tardivon A, Tanter M, Sigal-Zafrani B, Bercoff J, Deffieux T, et al. Breast Lesions- Quantitative Elastography With Supersonic Shear Imaging—Preliminary Results. Radiology (2010) 256(1):297–303. doi: 10.1148/radiol.10090385 [DOI] [PubMed] [Google Scholar]
  • 29. Evans A, Whelehan P, Thomson K, McLean D, Brauer K, Purdie C, et al. Quantitative Shear Wave Ultrasound Elastography- Initial Experience in Solid Breast Masses. Breast Cancer Res (2010) 12(6):R104. doi: 10.1186/bcr2787 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Berg WA, Cosgrove DO, Doré CJ, Schäfer FKW, Svensson WE, Hooley RJ, et al. Shear-Wave Elastography Improves the Specifi City of Breast US- The BE1 Multinational Study of 939 Masses. Radiology (2012) 262(2):435–49. doi:  10.1148/radiol.11110640/-/DC1 [DOI] [PubMed] [Google Scholar]
  • 31. Nightingale K, McAleavey S, Trahey G. Shear-Wave Generation Using Acoustic Radiation Force- In Vivo and Ex Vivo Results. Ultrasound Med Biol (2003) 29(12):1715–23. doi:  10.1016/S0301-5629(03)01080-9 [DOI] [PubMed] [Google Scholar]
  • 32. Chang JM, Moon WK, Cho N, Yi A, Koo HR, Han W, et al. Clinical Application of Shear Wave Elastography (SWE) in the Diagnosis of Benign and Malignant Breast Diseases. Breast Cancer Res Treat (2011) 129(1):89–97. doi:  10.1007/s10549-011-1627-7 [DOI] [PubMed] [Google Scholar]
  • 33. Herman J, Sedlackova Z, Furst T, Vachutka J, Salzman R, Vomacka J, et al. The Role of Ultrasound and Shear-Wave Elastography in Evaluation of Cervical Lymph Nodes. BioMed Res Int (2019) 2019:4318251. doi:  10.1155/2019/4318251 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Gemici AA, Ozal ST, Hocaoglu E, Inci E. Relationship Between Shear Wave Elastography Findings and Histologic Prognostic Factors of Invasive Breast Cancer. Ultrasound Q (2020) 36(1):79–83. doi:  10.1097/RUQ.0000000000000471 [DOI] [PubMed] [Google Scholar]
  • 35. Tozaki M, Fukuma E. Pattern Classification of ShearWave Elastography Images for Differential Diagnosis Between Benign and Malignant Solid Breast Masses. Acta Radiol (2011) 52(10):1069–75. doi:  10.1258/ar.2011.110276 [DOI] [PubMed] [Google Scholar]
  • 36. Azizi G, Faust K, Mayo ML, Farrell J, Malchoff C. Diagnosis of Thyroid Nodule With New Ultrasound Imaging Modalities. VideoEndocrinology (2019) 7(1). doi:  10.1089/ve.2020.0173 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Cirocchi R, Amabile MI, De Luca A, Frusone F, Tripodi D, Gentile P, et al. New Classifications of Axillary Lymph Nodes and Their Anatomical-Clinical Correlations in Breast Surgery. World J Surg Oncol (2021) 19(1):93. doi:  10.1186/s12957-021-02209-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Liu M, Wang CB, Xie F, Peng Y, Wang S, Chinese Society of Breast, S . Clinical Practice Guidelines for Diagnosis and Treatment of Invasive Breast Cancer: Chinese Society of Breast Surgery (CSBrS) Practice Guidelines 2021. Chin Med J (Engl) (2021) 134(9):1009–13. doi:  10.1097/CM9.0000000000001498 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Wen R, Dong J, Wang Y, Wang L. Combination of Color Doppler Ultrasound and CT for Diagnosing Breast Cancer. Am J Transl Res (2021) 13(9):10771–6. [PMC free article] [PubMed] [Google Scholar]
  • 40. Wang R, Zhu Y, Liu X, Liao X, He J, Niu L. The Clinicopathological Features and Survival Outcomes of Patients With Different Metastatic Sites in Stage IV Breast Cancer. BMC Cancer (2019) 19(1):1091. doi:  10.1186/s12885-019-6311-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Skerl K, Vinnicombe S, Giannotti E, Thomson K, Evans A. Influence of Region of Interest Size and Ultrasound Lesion Size on the Performance of 2D Shear Wave Elastography (SWE) in Solid Breast Masses. Clin Radiol (2015) 70(12):1421–7. doi:  10.1016/j.crad.2015.08.010 [DOI] [PubMed] [Google Scholar]
  • 42. Zhou J, Zhang B, Dong Y, Yu L, Gao T, Wang Z. Value on the Diagnosis of Axillary Lymph Node Metastasis in Breast Cancer by Color Doppler Ultrasound Combined With Computed Tomography. J BUON (2020) 25(4):1784–91. [PubMed] [Google Scholar]
  • 43. Wang J, Ben Z, Gao S, Lyu S, Wei X. The Role of Ultrasound Elastography and Virtual Touch Tissue Imaging in the Personalized Prediction of Lymph Node Metastasis of Breast Cancer. Gland Surg (2021) 10(4):1460–9. doi:  10.21037/gs-21-199 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Zhang Q, Agyekum EA, Zhu L, Yan L, Zhang L, Wang X, et al. Clinical Value of Three Combined Ultrasonography Modalities in Predicting the Risk of Metastasis to Axillary Lymph Nodes in Breast Invasive Ductal Carcinoma. Front Oncol (2021) 11:715097. doi:  10.3389/fonc.2021.715097 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Wen X, Yu X, Tian Y, Liu Z, Cheng W, Li H, et al. Quantitative Shear Wave Elastography in Primary Invasive Breast Cancers, Based on Collagen-S100A4 Pathology, Indicates Axillary Lymph Node Metastasis. Quant Imaging Med Surg (2020) 10(3):624–33. doi:  10.21037/qims.2020.02.18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Leng X, Japaer R, Zhang H, Yeerlan M, Ma F, Ding J. Relationship of Shear Wave Elastography Anisotropy With Tumor Stem Cells and Epithelial-Mesenchymal Transition in Breast Cancer. BMC Med Imaging (2021) 21(1):171. doi:  10.1186/s12880-021-00707-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Yang H, Wang R, Zeng F, Zhao J, Peng S, Ma Y, et al. Impact of Molecular Subtypes on Metastatic Behavior and Overall Survival in Patients With Metastatic Breast Cancer: A Single-Center Study Combined With a Large Cohort Study Based on the Surveillance, Epidemiology and End Results Database. Oncol Lett (2020) 20(4):87. doi:  10.3892/ol.2020.11948 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Cronin KA, Lake AJ, Scott S, Sherman RL, Noone AM, Howlader N, et al. Annual Report to the Nation on the Status of Cancer, Part I: National Cancer Statistics. Cancer (2018) 124(13):2785–800. doi:  10.1002/cncr.31551 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistic. CA Cancer J Clin (2021) 71(1):7–33. doi:  10.3322/caac.21654 [DOI] [PubMed] [Google Scholar]
  • 50. Magnoni F, Galimberti V, Corso G, Intra M, Sacchini V, Veronesi P. Axillary Surgery in Breast Cancer: An Updated Historical Perspective. Semin Oncol (2020) 47(6):341–52. doi:  10.1053/j.seminoncol.2020.09.001 [DOI] [PubMed] [Google Scholar]
  • 51. Zhao Q, Sun JW, Zhou H, Du LY, Wang XL, Tao L, et al. Pre-Operative Conventional Ultrasound and Sonoelastography Evaluation for Predicting Axillary Lymph Node Metastasis in Patients With Malignant Breast Lesions. Ultrasound Med Biol (2018) 44(12):2587–95. doi:  10.1016/j.ultrasmedbio.2018.07.017 [DOI] [PubMed] [Google Scholar]
  • 52. Hotton J, Salleron J, Henrot P, Buhler J, Leufflen L, Rauch P, et al. Pre-Operative Axillary Ultrasound With Fine-Needle Aspiration Cytology Performance and Predictive Factors of False Negatives in Axillary Lymph Node Involvement in Early Breast Cancer. Breast Cancer Res Treat (2020) 183(3):639–47. doi:  10.1007/s10549-020-05830-z [DOI] [PubMed] [Google Scholar]
  • 53. Du LW, Liu HL, Gong HY, Ling LJ, Wang S, Li CY, et al. Adding Contrast-Enhanced Ultrasound Markers to Conventional Axillary Ultrasound Improves Specificity for Predicting Axillary Lymph Node Metastasis in Patients With Breast Cancer. Br J Radiol (2021) 94(1118):20200874. doi:  10.1259/bjr.20200874 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54. Sarvazyan AP, Rudenko OV, Swanson SD, Fowlkes JB, Emelianov SY. Shear Wave Elasticity Imaging- a New Ultrasonic Technology of Medical Diagnostics. Ultrasound Med Biol (1998) 24(9):1419–35. doi: 10.1016/S0301-5629(98)00110-0 [DOI] [PubMed] [Google Scholar]
  • 55. Song EJ, Sohn YM, Seo M. Diagnostic Performances of Shear-Wave Elastography and B-Mode Ultrasound to Differentiate Benign and Malignant Breast Lesions: The Emphasis on the Cutoff Value of Qualitative and Quantitative Parameters. Clin Imaging (2018) 50:302–7. doi:  10.1016/j.clinimag.2018.05.007 [DOI] [PubMed] [Google Scholar]
  • 56. Han P, Yang H, Liu M, Cheng L, Wang S, Tong F, et al. Lymph Node Predictive Model With in Vitro Ultrasound Features for Breast Cancer Lymph Node Metastasis. Ultrasound Med Biol (2020) 46(6):1395–402. doi:  10.1016/j.ultrasmedbio.2020.01.030 [DOI] [PubMed] [Google Scholar]
  • 57. Hosonaga M, Saya H, Arima Y. Molecular and Cellular Mechanisms Underlying Brain Metastasis of Breast Cancer. Cancer Metastasis Rev (2020) 39(3):711–20. doi:  10.1007/s10555-020-09881-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58. Wei X, Wang M, Wang X, Zheng X, Li Y, Pan Y, et al. Prediction of Cervical Lymph Node Metastases in Papillary Thyroid Microcarcinoma by Sonographic Features of the Primary Site. Cancer Biol Med (2019) 16(3):587–94. doi:  10.20892/j.issn.2095-3941.2018.0310 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. Yang C, Dong J, Liu Z, Guo Q, Nie Y, Huang D, et al. Prediction of Metastasis in the Axillary Lymph Nodes of Patients With Breast Cancer: A Radiomics Method Based on Contrast-Enhanced Computed Tomography. Front Oncol (2021) 11:726240. doi:  10.3389/fonc.2021.726240 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Au FW, Ghai S, Lu FI, Moshonov H, Crystal P. Quantitative Shear Wave Elastography: Correlation With Prognostic Histologic Features and Immunohistochemical Biomarkers of Breast Cancer. Acad Radiol (2015) 22(3):269–77. doi:  10.1016/j.acra.2014.10.007 [DOI] [PubMed] [Google Scholar]
  • 61. Suvannarerg V, Chitchumnong P, Apiwat W, Lertdamrongdej L, Tretipwanit N, Pisarnturakit P, et al. Diagnostic Performance of Qualitative and Quantitative Shear Wave Elastography in Differentiating Malignant From Benign Breast Masses, and Association With the Histological Prognostic Factors. Quant Imaging Med Surg (2019) 9(3):386–98. doi:  10.21037/qims.2019.03.04 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62. Glechner A, Wockel A, Gartlehner G, Thaler K, Strobelberger M, Griebler U, et al. Sentinel Lymph Node Dissection Only Versus Complete Axillary Lymph Node Dissection in Early Invasive Breast Cancer: A Systematic Review and Meta-Analysis. Eur J Cancer (2013) 49(4):812–25. doi:  10.1016/j.ejca.2012.09.010 [DOI] [PubMed] [Google Scholar]
  • 63. Wockel A, Albert US, Janni W, Scharl A, Kreienberg R, Stuber T. The Screening, Diagnosis, Treatment, and Follow-Up of Breast Cancer. Dtsch Arztebl Int (2018) 115(18):316–23. doi:  10.3238/arztebl.2018.0316 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64. Cocco S, Leone A, Piezzo M, Caputo R, Di Lauro V, Di Rella F, et al. Targeting Autophagy in Breast Cancer. Int J Mol Sci (2020) 21(21). doi:  10.3390/ijms21217836 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65. Miricescu D, Totan A, Stanescu S, Badoiu SC, Stefani C, Greabu M. PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. Int J Mol Sci (2020) 22(1). doi:  10.3390/ijms22010173 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

RESOURCES